Patents by Inventor Rebecca Buonpane

Rebecca Buonpane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220233529
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 29, 2021
    Publication date: July 28, 2022
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • Publication number: 20210230294
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 29, 2021
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • Publication number: 20210230293
    Abstract: Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 29, 2021
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane
  • Publication number: 20210205311
    Abstract: The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 8, 2021
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • Publication number: 20200407429
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Applicant: MedImmune, LLC
    Inventors: Bret SELLMAN, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Patent number: 10730934
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 4, 2020
    Assignee: Medlmmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20190016787
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: January 25, 2018
    Publication date: January 17, 2019
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret SELLMAN, Christine TKACZYK, Partha S. CHOWDHURY, Lei HUA, Peter PAVLIK, Rebecca BUONPANE, Chew-Shun CHANG
  • Patent number: 9879070
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 30, 2018
    Assignee: MedImmune, LLC
    Inventors: Brett Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20150291685
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: November 6, 2013
    Publication date: October 15, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Publication number: 20110245153
    Abstract: Stabilized variable regions of the T cell receptor and methods of making the same using directed evolution through yeast display are provided. In one embodiment, the variable region is variable beta. In one embodiment, the stabilized T cell receptor variable regions have high affinity for a superantigen, such as TSST-1 or SEB. These T cell receptor variable regions are useful as therapeutics.
    Type: Application
    Filed: March 15, 2007
    Publication date: October 6, 2011
    Applicant: National Institutes of Health (NIH), U. S. Dept. of Health and Human Resources (DHHS) U. S. Govt.
    Inventors: David M. Kranz, Rebecca A. Buonpane, Hywyn R.O. Churchill, Eric J. Sundberg, Beenu Moza, Patrick Schlievert